Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CuraGen (CRGN) -- Ignore unavailable to you. Want to Upgrade?

To: Terp who wrote (51)	11/18/1998 8:48:00 PM
From: ahhaha	Read Replies (1) \| Respond to of 478

I've read it carefully. It doesn't say squat. It certainly is no reason to go long and you don't know why the stock was active today. To claim that this news item was the reason is a possible error of association and causality. There may be a reason to buy CRGN, but it isn't in this news release or it may be one of many reasons that in coming years these shares advance. That has little to do with current price action. I must add that vapid news release isn't a reason to hold short. The right action is to do nothing and wait for the stock to settle back down. If it will do that in so many weeks maybe you'll take a small long position and see what develops. If it rises, then you can add to your position assuming you have done the DD to give you the conviction to hold. If the stock just advances, I can't make any coherent suggestions about what to do.

To: Terp who wrote (51)	11/18/1998 10:13:00 PM
From: Pierre Borczuk	Respond to of 478

Check out HYSQ: They have the fastest sequencing system as well as the largest database and has filed patents on over 90,000 novel gene discoveries Hyseq, Inc., based in Sunnyvale, California, applies the proprietary DNA array technology of its integrated HyX(SM) genomics platform to produce gene-based therapeutic pharmaceutical product candidates, the only universal DNA sequencing chip, pharmacogenomics/polymorphism databases and gene-based diagnostic candidates. Hyseq believes that its fast-growing proprietary HyGenomics(TM) database of partial human DNA sample sequences is the world's largest. Information about Hyseq is available on the World Wide Web at hyseq.com or by phoning 408-524-8100. =================================== Functional Genomics Update Hyseq is leveraging its high throughput proprietary sequencing technology to identify valuable gene-based therapeutic target candidates. The Company's existing gene discovery program has identified a substantial collection of potential products, which are actively undergoing validation through its Functional Genomics Group. These targets encompass many of the body's major functions, including the cardiovascular system, central nervous system and immune and endocrine systems. In its effort to analyze the human genome, the Company has processed over 7.5 million sequences and has filed patents on over 95,000 novel gene discoveries. "Hyseq's success over the past year in developing the world's largest proprietary database of its kind, now enables us to take the next step towards marketing individual gene targets to pharmaceutical and major biotechnology companies through our HyProfileTM catalog, as per our business plan," said Mr. Gruber. Many of Hyseq's current gene targets are soluble factors and receptors, molecules that regulate normal and disease state physiology. Hyseq is validating as potential pharmaceutical targets molecules which include interleuklins, chemokines, growth factors, stem cell factors, interferons, integrins, hormones and their receptors.